Deficiency of perforin and hCNT1, a novel inborn error of pyrimidine metabolism, associated with a rapidly developing lethal phenotype due to multi-organ failure.


Journal

Biochimica et biophysica acta. Molecular basis of disease
ISSN: 1879-260X
Titre abrégé: Biochim Biophys Acta Mol Basis Dis
Pays: Netherlands
ID NLM: 101731730

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 17 08 2018
revised: 07 01 2019
accepted: 09 01 2019
pubmed: 19 1 2019
medline: 6 2 2020
entrez: 19 1 2019
Statut: ppublish

Résumé

Pyrimidine nucleotides are essential for a vast number of cellular processes and dysregulation of pyrimidine metabolism has been associated with a variety of clinical abnormalities. Inborn errors of pyrimidine metabolism affecting enzymes in the pyrimidine de novo and degradation pathway have been identified but no patients have been described with a deficiency in proteins affecting the cellular import of ribonucleosides. In this manuscript, we report the elucidation of the genetic basis of the observed uridine-cytidineuria in a patient presenting with fever, hepatosplenomegaly, persistent lactate acidosis, severely disturbed liver enzymes and ultimately multi-organ failure. Sequence analysis of genes encoding proteins directly involved in the metabolism of uridine and cytidine showed two variants c.1528C > T (p.R510C) and c.1682G > A (p.R561Q) in SLC28A1, encoding concentrative nucleotide transporter 1 (hCNT1). Functional analysis showed that these variants affected the three-dimensional structure of hCNT1, altered glycosylation and decreased the half-life of the mutant proteins which resulted in impaired transport activity. Co-transfection of both variants, mimicking the trans disposition of c.1528C > T (p.R510C) and c.1682G > A (p.R561Q) in the patient, significantly impaired hCNT1 biological function. Whole genome sequencing identified two pathogenic variants c.50delT; p.(Leu17Argfs*34) and c.853_855del; p.(Lys285del) in the PRF1 gene, indicating that our patient was also suffering from Familial Hemophagocytic Lymphohistiocytosis type 2. The identification of two co-existing monogenic defects might have resulted in a blended phenotype. Thus, the clinical presentation of isolated hCNT1 deficiency remains to be established.

Identifiants

pubmed: 30658162
pii: S0925-4439(19)30013-4
doi: 10.1016/j.bbadis.2019.01.013
pii:
doi:

Substances chimiques

Membrane Transport Proteins 0
Pyrimidines 0
cif nucleoside transporter 0
Perforin 126465-35-8
pyrimidine K8CXK5Q32L

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1182-1191

Subventions

Organisme : CIHR
ID : 301221
Pays : Canada

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Sandra Pérez-Torras (S)

Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona, Oncology Program, National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD), Institut de Recerca Sant Joan de Déu (IR SJD), 08028 Barcelona, Spain.

Aida Mata-Ventosa (A)

Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona, Oncology Program, National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD), Institut de Recerca Sant Joan de Déu (IR SJD), 08028 Barcelona, Spain.

Britt Drögemöller (B)

Faculty of Pharmaceutical Sciences, University of British Columbia, V6T 1Z3 Vancouver, British Columbia, Canada; BC Children's Hospital Research Institute, V5Z 4H4 Vancouver, British Columbia, Canada.

Maja Tarailo-Graovac (M)

Departments of Biochemistry, Molecular Biology and Medical Genetics, Cumming School of Medicine, University of Calgary, T2N 4N1 Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, T2N 4N1 Calgary, AB, Canada.

Judith Meijer (J)

Departments of Clinical Chemistry, Pediatrics and Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology & Metabolism, 1105 AZ Amsterdam, the Netherlands.

Rutger Meinsma (R)

Departments of Clinical Chemistry, Pediatrics and Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology & Metabolism, 1105 AZ Amsterdam, the Netherlands.

Arno G van Cruchten (AG)

Departments of Clinical Chemistry, Pediatrics and Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology & Metabolism, 1105 AZ Amsterdam, the Netherlands.

Wim Kulik (W)

Departments of Clinical Chemistry, Pediatrics and Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology & Metabolism, 1105 AZ Amsterdam, the Netherlands.

Albert Viel-Oliva (A)

Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona, Oncology Program, National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD), Institut de Recerca Sant Joan de Déu (IR SJD), 08028 Barcelona, Spain.

Axel Bidon-Chanal (A)

Departments of Nutrition, Food Science and Gastronomy, School of Pharmacy and Food Science, Institute of Biomedicine (IBUB), Institute of Theoretical and Computational Chemistry (IQTCUB), University of Barcelona, 08921 Santa Coloma de Gramenet, Spain.

Colin J Ross (CJ)

Faculty of Pharmaceutical Sciences, University of British Columbia, V6T 1Z3 Vancouver, British Columbia, Canada; BC Children's Hospital Research Institute, V5Z 4H4 Vancouver, British Columbia, Canada.

Wyeth W Wassermann (WW)

Departments of Pediatrics and Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, V5Z 4H4 Vancouver, Canada.

Clara D M van Karnebeek (CDM)

Departments of Clinical Chemistry, Pediatrics and Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology & Metabolism, 1105 AZ Amsterdam, the Netherlands; Departments of Pediatrics and Medical Genetics, Centre for Molecular Medicine and Therapeutics, University of British Columbia, V5Z 4H4 Vancouver, Canada.

Marçal Pastor-Anglada (M)

Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona, Oncology Program, National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD), Institut de Recerca Sant Joan de Déu (IR SJD), 08028 Barcelona, Spain. Electronic address: mpastor@ub.edu.

André B P van Kuilenburg (ABP)

Departments of Clinical Chemistry, Pediatrics and Clinical Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology & Metabolism, 1105 AZ Amsterdam, the Netherlands. Electronic address: a.b.vankuilenburg@amc.uva.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH